Intensity Therapeutics, Inc. (INTS) — DEF 14A Filings
All DEF 14A filings from Intensity Therapeutics, Inc.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
Intensity Therapeutics Seeks Reverse Stock Split to Maintain Nasdaq Listing
— Sep 9, 2025 Risk: high
Intensity Therapeutics, Inc. (INTS) is holding a Special Meeting on October 22, 2025, to seek stockholder approval for a reverse stock split of its common stock -
Intensity Therapeutics Goes Virtual for 2025 Annual Meeting
— Jun 2, 2025 Risk: low
INTENSITY THERAPEUTICS, INC. (INTS) filed a Definitive Proxy Statement (DEF 14A) on June 2, 2025, for its annual meeting scheduled for July 17, 2025, at 10:30 a -
Intensity Therapeutics Files Definitive Proxy Statement
— Jun 4, 2024 Risk: low
Intensity Therapeutics, Inc. filed a definitive proxy statement on June 4, 2024, for its annual meeting. The filing outlines the proposals to be voted on by sha
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX